Concerta. It appears that the FDA allowed the generic manufacturers to cut and paste the data from Concerta's pharmacokinetic studies and
In the laboratory clinical trials in children both CONCERTA and methylphenidate No differences in the pharmacokinetics of CONCERTA were noted following single
The data showed the methylphenidate hydrochloride ER products to be bioequivalent to Concerta based on FDA s understanding, at that time, of how the pharmacokinetics of Concerta contributed to
(Concerta). Table 2 details the pharmacokinetics of the various formulations. Table 2: Pharmacokinetics of Methylphenidate Formulations. Drug, Cmax (ng/mL)
CONCERTA once daily minimizes the fluctuations between peak and trough effect on the pharmacokinetics of CONCERTA. Hepatic insufficiency: There is
The data showed the methylphenidate hydrochloride ER products to be bioequivalent to Concerta based on FDA s understanding, at that time, of how the pharmacokinetics of Concerta contributed to
The pharmacokinetics of CONCERTA has not been studied in children less than 6 years of age. Renal Insufficiency. There is no experience with the use of CONCERTA
The data showed the methylphenidate hydrochloride ER products to be bioequivalent to Concerta based on FDA s understanding, at that time, of how the pharmacokinetics of Concerta contributed to
The data showed the methylphenidate hydrochloride ER products to be bioequivalent to Concerta based on FDA s understanding, at that time, of how the pharmacokinetics of Concerta contributed to
Comments